Expands Services, Offers Absolute Sample Protection
(Seattle, Wash.; Feb. 3, 2016) - LabConnect, a leading provider of highly customized global central laboratory services to biopharmaceutical, medical device and contract research organizations, has built a new biorepository facility to expand services and better meet the evolving needs of the industry.
LabConnect’s new, 5,000-square-foot biorepository in Johnson City, Tenn., features space for ambient, refrigerated, cold (-20C) and ultra-low temperature (-70C to -80C) storage as well as liquid nitrogen vapor phase storage (-190C).
“Proper sample management is essential to both today’s and tomorrow’s clinical trials,” said Eric Hayashi, LabConnect president and CEO. “Researchers depend on the integrity and availability of their stored biospecimens to retest them to verify trends or unexpected results, or for later retrieval to support specific biomarker research.”
With storage capacity for more than 8 million samples, LabConnect ensures the integrity of samples as well as business continuity with fully validated and mapped backup freezers and generators, redundant HVAC systems, whole building and biorepository security systems and a temperature monitoring system for all freezers and refrigerators with a 21 CFR Part 11 compliant audit trail.
“There are many biorepositories, but LabConnect’s facility is truly state-of-the art, using the most advanced technology available to provide the best protection in the industry for biospecimens,” said George Lewis, senior engineering technician at Johnson Controls, which supplies equipment to the Johnson City facility.
Additionally, through its SampleGISTICS™ system, LabConnect tracks sample locations and consolidates data within a centralized database accessible to researchers 24/7.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III POETYK PsA Trials Show Significant Clinical Benefit with Sotyktu in Psoriatic Arthritis
June 13th 2025New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in adults with active psoriatic arthritis, maintaining efficacy through 52 weeks of treatment.